Last reviewed · How we verify
sibutramine hydochloride monohydrate
Sibutramine is a norepinephrine-serotonin reuptake inhibitor that increases satiety and reduces appetite by blocking the reuptake of these neurotransmitters in the central nervous system.
Sibutramine is a norepinephrine-serotonin reuptake inhibitor that increases satiety and reduces appetite by blocking the reuptake of these neurotransmitters in the central nervous system. Used for Obesity management (withdrawn from most markets due to cardiovascular safety concerns).
At a glance
| Generic name | sibutramine hydochloride monohydrate |
|---|---|
| Also known as | ABT-991, sibutramine, Meridia |
| Sponsor | Abbott |
| Drug class | Norepinephrine-serotonin reuptake inhibitor (NSRI) |
| Target | Norepinephrine transporter (NET), serotonin transporter (SERT), dopamine transporter (DAT) |
| Modality | Small molecule |
| Therapeutic area | Obesity / Weight Management |
| Phase | FDA-approved |
Mechanism of action
Sibutramine works primarily by inhibiting the reuptake of norepinephrine and serotonin in the hypothalamus and other brain regions involved in appetite regulation. This increases the availability of these neurotransmitters at synaptic sites, leading to enhanced feelings of fullness and decreased hunger. The drug also has a minor effect on dopamine reuptake inhibition.
Approved indications
- Obesity management (withdrawn from most markets due to cardiovascular safety concerns)
Common side effects
- Hypertension
- Tachycardia
- Headache
- Dry mouth
- Insomnia
- Constipation
- Increased heart rate
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sibutramine hydochloride monohydrate CI brief — competitive landscape report
- sibutramine hydochloride monohydrate updates RSS · CI watch RSS
- Abbott portfolio CI